middl
east
respiratori
syndrom
mer
due
rna
betacoronaviru
merscov
infect
februari
world
health
organ
receiv
report
laboratoryconfirm
case
middl
east
europ
northern
africa
connect
middl
east
median
age
year
male
predomin
sever
case
deterior
rapidli
median
time
symptom
onset
icu
admiss
day
intub
day
icu
admiss
rate
mortal
amongst
critic
ill
ventil
patient
high
mortal
mortal
median
icu
stay
day
appar
epidemiolog
may
bias
select
report
sever
case
small
total
number
patient
make
suscept
distort
individu
outbreak
exampl
case
singl
outbreak
involv
three
healthcar
facil
includ
haemodialysi
unit
half
secondari
case
nosocomi
increas
preval
comorbid
bat
camel
implic
primari
anim
host
howev
data
conclus
human
human
transmiss
occur
rel
low
basic
reproduct
number
r
incub
period
approxim
day
day
mode
transmiss
unknown
rel
simpl
infect
control
measur
effect
control
nosocomi
outbreak
ex
vivo
model
merscov
rapidli
achiev
high
viral
load
infect
type
ii
alveolar
cell
cell
entri
appear
via
prolin
exopeptidas
receptor
express
lung
kidney
histolog
chang
includ
detach
type
ii
cell
basement
membran
disrupt
alveolar
tight
junction
chang
consist
apoptosi
viral
nucleic
acid
patient
faec
urin
suggest
direct
involv
gastrointestin
urinari
tract
present
nonspecif
fever
chill
sore
throat
myalgia
arthralgia
dyspnoea
vomit
diarrhoea
common
chest
xray
chang
consist
viral
pneumon
acut
respiratori
distress
syndrom
clinic
suspicion
therefor
depend
vigil
present
time
histori
travel
middl
east
contact
patient
respiratori
diseas
appropri
travel
histori
preval
organ
failur
difficult
determin
owe
report
limit
icu
data
possibl
duplic
report
case
howev
almost
icu
admiss
requir
mechan
ventil
recent
case
seri
report
critic
ill
patient
confirm
mer
one
probabl
mer
requir
invas
mechan
ventil
median
rang
pf
ratio
day
six
patient
requir
high
frequenc
oscil
nitric
oxid
prone
ventil
four
requir
combin
median
durat
ventil
day
five
receiv
noninvas
ventil
progress
invas
ventil
keep
report
acut
kidney
injuri
common
critic
ill
patient
requir
renal
replac
therapi
consist
report
shock
develop
patient
appear
moder
sever
routin
investig
neither
specif
sensit
lymphopenia
thrombocytopaenia
occur
onethird
patient
approxim
lymphocytosi
lactat
dehydrogenas
rais
half
hepat
transaminas
lower
respiratori
tract
specimen
prefer
due
higher
viral
load
oropharyng
nasopharyng
sampl
obtain
viral
shed
may
vari
time
repeat
sampl
recommend
patient
high
suspicion
merscov
infect
even
initi
result
neg
organ
identifi
blood
urin
stool
specimen
test
realtim
reversetranscript
polymeras
chain
reaction
merscov
rna
target
along
conjunctiv
swab
cerebr
spinal
fluid
conjunct
enceph
suspect
effect
diseasespecif
treatment
vaccin
earli
ribavirin
interferon
reduc
sever
respiratori
symptom
radiolog
inflammatori
marker
viral
load
rhesu
macaqu
monkey
ineffect
human
mer
ard
howev
may
due
late
administr
sever
diseas
evid
benefit
high
dose
steroid
sar
data
indic
signific
risk
harm
manag
algorithm
given
fig
current
epidem
pandem
risk
appear
low
estim
r
number
secondari
infect
gener
primari
infect
suscept
popul
rang
number
less
transmiss
guarante
fade
away
greater
risk
epidem
littl
ie
transmiss
may
fade
away
anyway
howev
number
caveat
firstli
r
difficult
estim
secondli
coronavirus
rapidli
adapt
new
host
process
may
becom
infecti
thirdli
exist
mild
perhap
unidentifi
case
make
infect
control
measur
less
like
effect
approxim
mer
case
may
undiagnos
fourthli
signific
epidem
pose
major
challeng
intens
care
owe
prolong
durat
mechan
ventil
high
requir
renal
replac
therapi
noninvas
ventil
appear
use
except
possibl
delay
intub
may
increas
diseas
transmiss
risk
undu
delay
intub
four
patient
receiv
cpap
suffer
six
cardiac
arrest
mode
transmiss
unknown
implement
airborn
contact
precaut
prove
unnecessari
person
protect
equip
airborn
transmiss
includ
fittest
equival
face
mask
fit
test
timeconsum
carri
advanc
hospit
admiss
patient
mer
delay
onset
symptom
icu
admiss
short
visit
without
full
person
protect
equip
associ
nosocomi
transmiss
visitor
also
fittest
